BioCentury
ARTICLE | Financial News

Gilead's 3Q13 earnings beat Street

October 30, 2013 12:53 AM UTC

Gilead Sciences Inc. (NASDAQ:GILD) reported 3Q13 non-GAAP diluted EPS of $0.52, beating the Street's estimate of $0.48 and up from $0.50 in 3Q12. Total revenues for the quarter were $2.78 billion, up 15% from $2.43 billion in 3Q12. The Street was expecting $2.72 billion in revenues. The company reported $144 million in 3Q13 worldwide sales of HIV drug Stribild elvitegravir/cobicistat/emtricitabine/tenofovir. The European Commission approved Stribild in May and FDA approved the once-daily tablet in August 2012. Gilead raised its 2013 net product sales guidance to $10.3-$10.4 billion from $10-$10.2 billion. ...